The PERT Consortium CEO Michelle Lanno to Step Down at Year’s End

July 20, 2026—Michelle Lanno, Chief Executive Officer of The PERT Consortium, announced she will be stepping down from her role effective December 31, concluding more than a decade of leadership that began with the organization’s founding in 2015.

Multisociety Comments Submitted to CMS on Proposed Decision on NCD for TAVR

July 20, 2026—The Society for Cardiovascular Angiography & Interventions (SCAI) announced that, in collaboration with the American College of Cardiology (ACC) and the Society of Thoracic Surgeons (STS), the societies have submitted comments to the Centers for Medicare and Medicaid Services (CMS) on areas needing clarification in the CMS proposed decision on the National Coverage Determination (NCD; CAG-00430R2).

ElectroWire’s LightningWire Transseptal Puncture System Receives FDA Clearance

July 16, 2026—ElectroWire Medical announced that the FDA has granted 510(k) clearance for its LightningWire transseptal puncture system, which is indicated to create an atrial septal defect in the heart, whereby various cardiovascular catheters are introduced.

Immediate Adoption of Enhanced Radiation Protection in Catheterization Labs Recommended in Multisociety Statement

July 14, 2026—The Society for Cardiovascular Angiography and Interventions (SCAI) announced that a multisociety expert consensus statement on radiation protection in catheterization labs was published by David G. Rizik, MD, et al in JSCAI.

Stereotaxis Completes Acquisition of Robocath

July 13, 2026—Stereotaxis announced that it has completed its previously announced acquisition of Robocath, a Rouen, France-based developer of robotic technologies for interventional cardiology and neurointerventions.

First Patient Enrolled in ENHANCE EFS of Nyra’s Carlen TMVR System for FMR

July 10, 2026—Nyra Medical, Inc. announced enrollment of the first patient in the ENHANCE early feasibility study (EFS) of the company’s investigational Carlen system.

TRICURE US Pivotal Study Begins for TriCares’ Topaz TTVR System

July 10, 2026—TriCares SAS announced that the first patient has been enrolled and treated in the TRICURE United States investigation device exemption (IDE) pivotal study, which is evaluating the company’s Topaz transcatheter tricuspid valve replacement (TTVR) system in the treatment of tricuspid regurgitation (TR).

GLP-1 RAs Linked to Lower Mortality, Amputation Risk in PAD and Type 2 Diabetes

July 6, 2026—Glucagon‐like peptide‐1 receptor agonists (GLP-1 RAs) were shown to be associated with lower risks of death, hospitalization, amputation, and lower-extremity revascularization compared with metformin among adults with type 2 diabetes and peripheral artery disease (PAD), according to the American Heart Association.